Amylyx Pharmaceuticals, Inc., was incorporated under the laws of the State of Delaware on January 10, 2014. The company is a clinical-stage pharmaceutical company with a mission to develop and advance new therapies for communities with unmet medical needs. The company has ongoing preclinical and clinical development programs in neurodegenerative and endocrine diseases. The company is advancing a pipeline in which it has matched investigational therapies to the diseases in which it believes these therapies can have the greatest impact, based on well-defined mechanistic principles, clear clinical outcomes and biomarkers, and rigorous preclinical data, independent of patterns. 

AMLX

AMLX Profile